EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, announced today that it has created an Optometry Advisory Board to help oversee the development, marketing and medical use of NovaBay’s i-LidTM Cleanser and other eye care products.
The five members of the new board are nationally known optometrists: Dr. Katherine M. Mastrota, Center Director of Omni Eye Surgery in New York City; Dr. Arthur Epstein, Director of the Dry Eye - Ocular Surface Disease Center and Director of Clinical Research at Phoenix Eye Care; Dr. William Townsend, Optometrist in Houston, TX, and Distinguished Visiting Clinician in Residence at the University of Houston College of Optometry; Dr. Scot Morris, owner and medical director of Eye Consultants of Colorado, LLC, in Conifer, CO; and Dr. Paul Karpecki, head of the ocular surface disease clinic and director of clinical research at Koffler Vision Group in Lexington, Kentucky.
“The U.S. has 32,000 optometrists, who provide eye care services to millions of Americans,” said Dr. Ron Najafi, Chairman and CEO of NovaBay. “Our new board will play a vital role getting information to those optometrists about the benefits that i-Lid Cleanser offers to those patients.”
Indeed, the board members have shown in their own practices that i-Lid Cleanser helps patients manage such conditions as blepharitis and dry-eye syndrome, which affect an estimated 40 million Americans. As Dr. Mastrota noted in the August 10, 2014 issue of Contact Lenses Today, i-Lid Cleanser “has proven useful in the treatment of chronic wounds for removing micro-organisms and biofilms” and offers a “great opportunity…in the management of eyelid disease.”
i-Lid Cleanser ideal for the management of common and potentially sight-threatening eye conditions, such as blepharitis, where Staphylococci bacteria grow on eyelids, causing swelling, redness, inflammation, irritation and a crusty build-up. Patients who’ve had blepharitis for years report—along with their doctors—that i-Lid Cleanser has finally brought relief from the often-painful condition. “i-Lid Cleanser removes both the bacteria and the bacterial toxins,” said board member Dr. Arthur Epstein. “It works extremely well for this condition.”
“The fact that five of the nation’s top optometrists have agreed to serve on our new Optometry Advisory Board is evidence that i-Lid Cleanser is a breakthrough product that can make a real difference in patients’ lives,” said Dr. Najafi.
This release contains forward-looking statements and opinions regarding the efficacy and commercial potential of i-Lid Cleanser, which are based upon the company and the advisory board’s current expectations, assumptions, estimates, projections and beliefs. The words “believe” and “will” are intended to identify the forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to any possible unexpected adverse side effects or inadequate therapeutic efficacy of i-Lid Cleanser, and the risk that potential customers will not perceive the benefits of i-Lid Cleanser in the same light as the company and/or advisory board. Other risks relating to NovaBay and its products, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay's latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading "Risk Factors." The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
Stay informed on NovaBay's progress: